Hepatitis C viral kinetics in special populations
Tóm tắt
Từ khóa
Tài liệu tham khảo
National Institutes of Health: National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002, 36:S3–S20.
Nguyen TT, Sedghi-Vaziri A, Wilkes LB, et al.: Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996, 3:75–78.
Neumann AU, Lam NP, Dahari H, et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103–107.
Neumann AU, Lam NP, Dahari H, et al.: Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000, 182:28–35.
Bergmann CC, Layden JE, Levy-Drummer RS, et al.: Clinical implications of a new tri-phasic model for hepatitis C viral kinetics during IFN-alpha therapy [abstract]. Hepatology 2001, 34:345A.
Herrmann E, Lee JH, Marinos G, et al.: Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37:1351–1358.
Kieffer TL, Sarrazin C, Miller JS, et al.: Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46:631–639.
Garcia-Retortillo M, Forns X, Feliu A, et al.: Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002, 35:680–687.
Dahari H, Feliu A, Garcia-Retortillo M, et al.: Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005, 42:491–498.
Powers KA, Ribeiro RM, Patel K, et al.: KInetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006, 12:207–216.
Schiano TD, Gutierrez JA, Walewski JL, et al.: Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005, 42:1420–1428.
Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123–126.
Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117–122.
Dahari H, Major M, Zhang X, et al.: Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 2005, 128:1056–1066.
Powers KA, Dixit NM, Ribeiro RM, et al.: Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003, 23(Suppl 1):13–18.
Talal AH, Ribeiro RM, Powers KA, et al.: Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006, 43:943–953.
Ribeiro RM, Layden-Almer J, Powers KA, et al.: Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003, 38:509–517.
Colombatto P, Civitano L, Oliveri F, et al.: Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003, 8:519–530.
Lam NP, Neumann AU, Gretch DR, et al.: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997, 26:226–231.
Blight KJ, Kolykhalov AA, Rice CM: Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972–1974.
Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922–924.
Layden-Almer JE, Ribeiro RM, Wiley T, et al.: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003, 37:1343–1350.
Bortoletto G, Realdon S, Dal Pero F, et al.: Insulin resistance (IR) defined by the homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during pegylated-interferon therapy for chronic hepatitis C [abstract]. Hepatology 2007, 46:361A.
Lam NP, Pitrak D, Speralakis R, et al.: Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997, 42:178–185.
Westin J, Lagging M, Dhillon AP, et al.: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007, 14:29–35.
Medeiros-Filho JE, de Carvalho Mello IM, Pinho JR, et al.: Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J Gastroenterol 2006, 12:7271–7277.
Cotler SJ, Layden JE, Neumann AU, Jensen DM: First phase hepatitis c viral kinetics in previous nonresponders patients. J Viral Hepat 2003, 10:43–49.
Neumann AU, Mohan P, Lutchman G, et al.: Hepatitis C viral kinetics in children treated with PEGIFN alfa-2a [abstract]. Hepatology 2004, 40(Suppl 1):473A.
Torriani FJ, Ribeiro RM, Gilbert TL, et al.: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003, 188:1498–1507.
Layden JE, Layden TJ, Reddy KR, et al.: First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002, 9:340–345.
Jessner W, Gschwantler M, Steindl-Munda P, et al.: Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001, 358:1241–1242.
Dahari H, Markatou M, Zeremski M, et al.: Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007, 47:23–30.
Sherman KE, Shire NJ, Rouster SD, et al.: Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005, 128:313–327.
Sarrazin C, Kieffer TL, Bartels D, et al.: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767–1777.
Pawlotsky JM, Dahari H, Neumann AU, et al.: Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004, 126:703–714.
Zeuzem S, Herrmann E, Lee JH, et al.: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001, 120:1438–1447.
Pilli M, Zerbini A, Penna A, et al.: HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007, 133:1132–1143.
Inoue K, Umehara T, Ruegg UT, et al.: Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 2007, 45:921–928.
Dahari H, Perelson AS: Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology 2007, 46:2048–2049.
Lindh M, Alestig E, Arnholm B, et al.: Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol 2007, 45:2439–2445.
Dahari H, Perelson AS: Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss. World J Gastroenterol 2007, 13:3020–3021.
Levy-Drummer RS, Haagmans BL, Soulier A, et al.: Pharmacodynamic modeling of HCV kinetics during peg-interferon-alfa-2a (40KD) and ribavirin treatment of chronic hepatitis C genotype 1 patients in the DITTO-HCV study [abstract]. Hepatology 2004, 40:390A.
Bekkering FC, Neumann AU, Brouwer JT, et al.: Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 2001, 1:14.
Dahari H, Lo A, Ribeiro RM, Perelson AS: Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 2007, 247:371–381.
Wein LM, D’Amato RM, Perelson AS: Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol 1998, 192:81–98.
Callaway DS, Perelson AS: HIV-1 infection and low steady state viral loads. Bull Math Biol 2002, 64:29–64.
Pal S, Shuhart MC, Thomassen L, et al.: Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo. J Virol 2006, 80:2280–2290.
Everson GT, Hoefs JC, Seeff LB, et al.: Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006, 44:1675–1684.
Iacobellis A, Siciliano M, Perri F, et al.: Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007, 46:206–212.